---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-005006"
form_type: "8-K"
ticker: "STIM"
cik: "0001227636"
company_name: "Neuronetics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:52:21.081096+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Neuronetics reports preliminary Q4 revenue $22.1M, FY2024 $74.5M; issues 2025 guidance with 12-19% growth

## Summary
- Preliminary Q4 2024 revenue $22.1M; full-year 2024 revenue $74.5M (combined with Greenbrook from Dec 9).
- Closed acquisition of Greenbrook TMS Dec 9, 2024; expects over $22M annualized cost synergies.
- FY2025 revenue guidance $145M-$155M, pro forma growth 12-19%; gross margin ~55%.
- Expects cash flow breakeven in Q3 2025; reduced cash burn in H1 2025.
- Launched Better Me Provider program with over 350 sites; FDA clearance for adolescent MDD expanded TAM by 35%.

## SEC filing metadata
- accession: 0001193125-25-005006
- form_type: 8-K
- ticker: STIM
- cik: 0001227636
- company_name: Neuronetics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1227636/000119312525005006/0001193125-25-005006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1227636/000119312525005006/d925718d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-005006
- JSON: https://secwatch.observer/filing/0001193125-25-005006.json
- Plain text: https://secwatch.observer/filing/0001193125-25-005006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.